1. Home
  2. HURN vs RARE Comparison

HURN vs RARE Comparison

Compare HURN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

HOLD

Current Price

$177.47

Market Cap

2.8B

ML Signal

HOLD

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$22.60

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HURN
RARE
Founded
2002
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.3B
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
HURN
RARE
Price
$177.47
$22.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
19
Target Price
$215.50
$73.11
AVG Volume (30 Days)
145.5K
4.0M
Earning Date
02-24-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
32.32
N/A
EPS
5.98
N/A
Revenue
$1,618,977,000.00
$630,598,000.00
Revenue This Year
$14.19
$19.68
Revenue Next Year
$9.49
$19.44
P/E Ratio
$29.87
N/A
Revenue Growth
12.67
20.63
52 Week Low
$120.25
$18.41
52 Week High
$186.78
$46.50

Technical Indicators

Market Signals
Indicator
HURN
RARE
Relative Strength Index (RSI) 46.93 34.75
Support Level $179.53 $22.00
Resistance Level $186.59 $24.65
Average True Range (ATR) 5.42 1.28
MACD -0.66 0.08
Stochastic Oscillator 39.82 22.33

Price Performance

Historical Comparison
HURN
RARE

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: